ClinicalTrials.gg
CompletedNCT06784349Updated Mar 16, 2026

ALN-APOC3 in Adult Participants With Dyslipidemia

A Phase 1 interventional study of ALN-APOC3 and Matching Placebo in Dyslipidemia, sponsored by Regeneron Pharmaceuticals. Completed at 1 site in Moldova. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This study is researching an experimental drug called ALN-APOC3 (called "study drug"). The study is focused on participants who have dyslipidemia (abnormal amounts of fats in the blood, including triglycerides and cholesterol), but who are otherwise healthy.

The aim of the study is to see how safe and effective the study drug is.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood at different times
  • How the study drug changes lipid levels in the blood
02

Conditions studied

  • Dyslipidemia

Browse trials for

Keywords

  • Lipids
  • Triglycerides
  • Cholesterol
03

In context

Dyslipidemias

1,250 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.

This study's enrollment of 32 is below the median of 100 across 987 interventional studies indexed under Dyslipidemias.

Browse Dyslipidemias studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 413 studies on the registry; 91 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 80 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Judged by the investigator to be in good health based on medical history, physical examination, vital signs, (ECG's) and laboratory safety testing, as defined in the protocol
  2. Participants can enter the study under one of the following options, as defined in the protocol:

    1. Currently not taking statin and have not been on statin therapy for the 3 months prior to screening, or
    2. On a stable dose of statin, taken continuously for 3 months
  3. Fasting triglycerides concentrations ≥100 and \<500 mg/dL (1.13 to 5.65 mmol/L) during screening visit, as defined in the protocol
  4. Fasting LDL-C ≥70 (1.81 mmol/L) if on stable statin therapy OR if not on statin treatment, as defined in the protocol

Key Exclusion Criteria:

  1. History of cardiovascular (other than dyslipidemia), respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, or any other concern, as assessed by the investigator that may confound the results of the study or poses an additional risk to the participant by study participation
  2. Was hospitalized (ie, >24 hours) for any reason within 30 days of the screening visit
  3. Is positive for (HIV) or surface Antigen (HBsAg) at the screening visit, as defined in the protocol
  4. Is positive for antibody and positive for qualitative Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) test at the screening visit
  5. Any , except for non-melanoma skin cancer or cervical/anus in-situ, that have been resected with no evidence of disease for 3 years prior to the screening visit

NOTE: Other protocol defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    ALN-APOC3 Ascending Cohorts

    Part A: Ascending Cohorts Randomized as described in the protocol May include optional cohorts

    Drug: ALN-APOC3 · Drug: Matching Placebo

  • Placebo comparator
    Placebo

    Part A and Part B: Randomized as described in the protocol

    Drug: Matching Placebo

  • Experimental
    ALN-APOC3 low-dose

    Part B: Parallel Arm Randomized as described in the protocol

    Drug: ALN-APOC3

  • Experimental
    ALN-APOC3 medium-dose

    Part B: Parallel Arm Randomized as described in the protocol

    Drug: ALN-APOC3

  • Experimental
    ALN-APOC3 high-dose

    Part B: Parallel Arm Randomized as described in the protocol

    Drug: ALN-APOC3

Interventions

  • DrugALN-APOC3

    Administered as per the protocol

  • DrugMatching Placebo

    Administered as per the protocol

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events (TEAEs)

    Time frame: Through Week 44

  2. Severity of TEAEs

    Time frame: Through Week 44

  3. Percent changes in fasting concentrations of High-Density Lipoprotein Cholesterol (HDL-C)

    Part B Only

    Time frame: Baseline to week 24

Secondary outcomes

  1. Concentration of combined ALN-APOC3 and metabolites in plasma

    Time frame: Through Week 44

  2. Urinary excretion of combined ALN-APOC3 and metabolites

    Part A Only

    Time frame: Through 24 Hours, After Treatment

  3. Percent change in fasting concentrations of APOC3

    Time frame: Baseline to Week 12

  4. Absolute change in fasting concentrations of APOC3

    Time frame: Baseline to Week 12

  5. Percent change in fasting concentrations of APOC3

    Part B Only

    Time frame: Baseline to Week 24

  6. Absolute change in fasting concentrations of APOC3

    Part B Only

    Time frame: Baseline to Week 24

  7. Percent change in fasting concentrations of HDL-C

    Time frame: Baseline to Week 12

  8. Absolute change in fasting concentrations of HDL-C

    Time frame: Baseline to Week 12

  9. Absolute change in fasting concentrations of HDL-C

    Part B Only

    Time frame: Baseline to Week 24

  10. Percent change in fasting concentrations of Low-Density Lipoprotein Cholesterol (LDL-C)

    Time frame: Baseline to Week 12

  11. Absolute change in fasting concentrations of LDL-C

    Time frame: Baseline to Week 12

  12. Percent change in fasting concentrations of LDL-C

    Part B Only

    Time frame: Baseline to Week 24

  13. Absolute change in fasting concentrations of LDL-C

    Part B Only

    Time frame: Baseline to Week 24

  14. Percent change in fasting concentrations of Triglycerides (TG)

    Time frame: Baseline to Week 12

  15. Absolute change in fasting concentrations of TG

    Time frame: Baseline to Week 12

  16. Percent change in fasting concentrations of TG

    Part B Only

    Time frame: Baseline to Week 24

  17. Absolute change in fasting concentrations of TG

    Part B Only

    Time frame: Baseline to Week 24

  18. Percent change in fasting concentrations of non-HDL-C

    Time frame: Baseline to Week 12

  19. Absolute change in fasting concentrations of non-HDL-C

    Time frame: Baseline to Week 12

  20. Percent change in fasting concentrations of non-HDL-C

    Part B Only

    Time frame: Baseline to Week 24

  21. Absolute change in fasting concentrations of non-HDL-C

    Part B Only

    Time frame: Baseline to Week 24

  22. Percent change in fasting concentrations of Apolipoprotein-B (APOB)

    Time frame: Baseline to Week 12

  23. Absolute change in fasting concentrations of APOB

    Time frame: Baseline to Week 12

  24. Percent change in fasting concentrations of APOB

    Part B Only

    Time frame: Baseline to Week 24

  25. Absolute change in fasting concentrations of APOB

    Part B Only

    Time frame: Baseline to Week 24

07

Study locations

1 site
  • Arensia Exploratory Medicine at the Republican Clinical Hospital
    Chisinau, 2025, Moldova
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Feb 2026, 12 months.

Of 77 industry-sponsored phase 1 interventional studies under Dyslipidemias, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 12 months is above that.

Counting every sponsor, half of 83 studies reached it within 2 months; a quarter within 1 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2024
First posted
Jan 20, 2025
StartActual
Jan 27, 2025
Primary completionActual
Feb 25, 2026
CompletionActual
Feb 25, 2026
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06784349
Responsible party
Sponsor
First posted
Jan 20, 2025
Start date
Jan 27, 2025
Primary completion
Feb 25, 2026
Completion
Feb 25, 2026
Last update
Mar 16, 2026

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion